Schlomm T, Börgermann C,
Heinzer H, Rübben H, Huland H, Graefen M. Role of
lymphnode dissection in prostate cancer. Urologe A. 2008 Dec 18.
Walz J, Chun FK, Klein EA, Reuther A, Saad F, Graefen M, Huland H,
Karakiewicz PI. Nomogram Predicting the Probability of Early Recurrence
After Radical Prostatectomy for Prostate Cancer. J Urol. 2008 Dec 12.
Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P,
Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M,
Erbersdobler A. Distinct subcellular expression patterns of neutral
endopeptidase (CD10) in prostate cancer predict diverging clinical courses
in surgically treated patients. Clin Cancer Res. 2008 Dec
1;14(23):7838-42.
Eisen T, Oudard S, Szczylik C, Gravis G, Heinzer H, Middleton R,
Cihon F, Anderson S, Shah S, Bukowski R, Escudier B; TARGET Study Group.
Sorafenib for older patients with renal cell carcinoma: subset analysis
from a randomized trial. J Natl Cancer Inst. 2008 Oct 15;100(20):1454-63.
Heuer R, Eichelberg C, Heinzer H. Rebuttal from Authors re: Sergio
Bracarda, Valeria De Simone. Sequential Therapies in Metastatic Renal Cell
Carcinoma: Option or Strategy? Eur Urol 2008;54:1219-20. Eur Urol. 2008
Dec;54(6):1221-2.
Eichelberg C, Heuer R, Chun FK, Hinrichs K, Zacharias M, Huland H,
Heinzer H. Sequential use of the tyrosine kinase inhibitors sorafenib and
sunitinib in metastatic renal cell carcinoma: a retrospective outcome
analysis. Eur Urol. 2008 Dec;54(6):1373-8.
Salomon G, Köllerman J, Thederan I, Chun FK, Budäus L, Schlomm T,
Isbarn H, Heinzer H, Huland H, Graefen M. Evaluation of prostate cancer
detection with ultrasound real-time elastography: a comparison with step
section pathological analysis after radical prostatectomy. Eur Urol. 2008
Dec;54(6):1354-62.
Köllermann J, Schlomm T, Bang H, Schwall GP, von Eichel-Streiber C,
Simon R, Schostak M, Huland H, Berg W, Sauter G, Klocker H, Schrattenholz
A. Expression and prognostic relevance of annexin a3 in prostate cancer. Eur
Urol. 2008 Dec;54(6):1314-23.
Jeldres C, Suardi N, Walz J, Hutterer GC, Ahyai S, Lattouf JB,
Haese A, Graefen M, Erbersdobler A, Heinzer H, Huland H, Karakiewicz PI.
Validation of the contemporary Epstein criteria for insignificant prostate
cancer in European men. Eur Urol. 2008 Dec;54(6):1306-13.
Capitanio U, Ahyai S, Graefen M, Jeldres C, Shariat SF,
Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H, Perrotte P,
Péloquin F, Pharand D, Arjane P, Huland H, Karakiewicz PI. Assessment of
biochemical recurrence rate in patients with pathologically confirmed
insignificant prostate cancer. Urology. 2008 Dec;72(6):1208-11; discussion
1212-3.
Walz J, Chun FK, Klein EA, Reuther A, Graefen M, Huland H,
Karakiewicz PI. Risk-Adjusted Hazard Rates of Biochemical Recurrence for
Prostate Cancer Patients after Radical Prostatectomy. Eur Urol. 2008 Nov
20.
Walz J, Haese A, Scattoni V, Steuber T, Chun FK, Briganti A,
Montorsi F, Graefen M, Huland H, Karakiewicz PI. Percent free
prostate-specific antigen (PSA) is an accurate predictor of prostate
cancer risk in men with serum PSA 2.5 ng/mL and lower. Cancer. 2008 Nov
15;113(10):2695-703.
Isbarn H, Jeldres C, Budäus L, Salomon G, Schlomm T, Steuber T,
Chun FK, Ahyai S, Capitanio U, Haese A, Heinzer H, Huland H, Graefen M,
Karakiewicz P. Effect of Body Mass Index on Histopathologic Parameters:
Results of Large European Contemporary Consecutive Open Radical
Prostatectomy Series. Urology. 2008 Nov 15.
Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A,
Mulders PF, Huland H, Abbou CC, Remzi M, Tinzl M, Feyerabend S,
Stillebroer AB, van Gils MP, Schalken JA. Clinical utility of the PCA3
urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008
Nov;54(5):1081-8.
Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher
M, Schlomm T. Prevalence of human gammaretrovirus XMRV in sporadic
prostate cancer. J Clin Virol. 2008 Nov;43(3):277-83.
Schlomm T, Iwers L, Kirstein P, Jessen B, Köllermann J, Minner S,
Passow-Drolet A, Mirlacher M, Milde-Langosch K, Graefen M, Haese A,
Steuber T, Simon R, Huland H, Sauter G, Erbersdobler A. Clinical
significance of p53 alterations in surgically treated prostate cancers. Mod
Pathol. 2008 Nov;21(11):1371-8.
Suardi N, Capitanio U, Chun FK, Graefen M, Perrotte P, Schlomm T,
Haese A, Huland H, Erbersdobler A, Montorsi F, Karakiewicz PI. Currently
used criteria for active surveillance in men with low-risk prostate
cancer: an analysis of pathologic features. Cancer. 2008 Oct
15;113(8):2068-72.
Yossepowitch O, Bjartell A, Eastham JA, Graefen M, Guillonneau BD, Karakiewicz
PI, Montironi R, Montorsi F. Positive Surgical Margins in Radical
Prostatectomy: Outlining the Problem and Its Long-Term Consequences. Eur
Urol. 2008 Oct 1.
Montorsi F, Brock G, Lee J, Shapiro J, Van Poppel H, Graefen M,
Stief C. Effect of nightly versus on-demand vardenafil on recovery of
erectile function in men following bilateral nerve-sparing radical
prostatectomy. Eur Urol. 2008 Oct;54(4):924-31.
Briganti A, Capitanio U, Chun FK, Gallina A, Suardi N, Salonia A,
Da Pozzo LF, Colombo R, Di Girolamo V, Bertini R, Guazzoni G, Karakiewicz
PI, Montorsi F, Rigatti P. Impact of surgical volume on the rate of lymph
node metastases in patients undergoing radical prostatectomy and extended
pelvic lymph node dissection for clinically localized prostate cancer. Eur
Urol. 2008 Oct;54(4):794-802.
Bhojani N, Ahyai S, Graefen M, Capitanio U, Suardi N, Shariat SF,
Jeldres C, Erbersdobler A, Schlomm T, Haese A, Steuber T, Heinzer H,
Montorsi F, Huland H, Karakiewicz PI. Partin Tables cannot accurately
predict the pathological stage at radical prostatectomy. Eur J Surg Oncol.
2008 Sep 9.
Erbersdobler A, Kollermann J, Graefen M, Röcken C, Schlomm T. Seminal
vesicle amyloidosis does not provide any protection from invasion by
prostate cancer. BJU Int. 2008 Sep 3.
Graefen M. Editorial Comment on: Recovery of Urinary Continence
after Radical Prostatectomy: Association with Urethral Length and Urethral
Fibrosis Measured by Preoperative and Postoperative Endorectal Magnetic
Resonance Imaging. Eur Urol. 2008 Sep 2.
Chun FK, Briganti A. Editorial comment on: preliminary results of a
novel method to estimate the probability of prostate cancer in men with
elevated serum PSA values. Eur Urol. 2008 Sep;54(3):702.
Chun FK, Haese A, Ahyai SA, Walz J, Suardi N, Capitanio U, Graefen
M, Erbersdobler A, Huland H, Karakiewicz PI. Critical assessment of tools
to predict clinically insignificant prostate cancer at radical
prostatectomy in contemporary men. Cancer. 2008 Aug 15;113(4):701-9.
Isbarn H, Ahyai SA, Chun FK, Budäus L, Schlomm T, Salomon G,
Zacharias M, Erbersdobler A, Köllermann J, Sauter G, Huland H, Graefen M,
Steuber T. Prevalence of a Tertiary Gleason Grade and Its Impact on
Adverse Histopathologic Parameters in a Contemporary Radical Prostatectomy
Series. Eur Urol. 2008 Aug 13.
Jeldres C, Suardi N, Capitanio U, Montorsi F, Shariat SF, Perrotte
P, Peloquin F, Pharand D, Graefen M, Karakiewicz PI. High surgical volume
is associated with a lower rate of secondary therapy after radical
prostatectomy for localized prostate cancer. BJU Int. 2008 Aug;102(4):463-7.
Chun FK, Karakiewicz PI, Briganti A. Prostate Cancer Diagnosis:
Importance of Individualized Risk Stratification Models over PSA Alone. Eur
Urol. 2008 Aug;54(2):241-2.
Briganti A, Chun FK, Karakiewicz PI, Rigatti P, Montorsi F. Is
node-positive prostate cancer always a systemic disease? Eur Urol. 2008
Aug;54(2):243-6.
Chun FK. Editorial Comment on: (11)C-Choline-Positron Emission
Tomography/Computerized Tomography for Preoperative Lymph-Node Staging in
Intermediate-Risk and High-Risk Prostate Cancer: Comparison with Clinical
Staging Nomograms. Eur Urol. 2008 Aug;54(2):400-1.
Gallina A, Suardi N, Montorsi F, Capitanio U, Jeldres C, Saad F,
Graefen M, Shariat SF, Widmer H, Arjane P, Péloquin F, Perrotte P, Karakiewicz
PI. Mortality at 120 days after prostatic biopsy: a population-based study
of 22,175 men. Int J Cancer. 2008 Aug 1;123(3):647-52.
Graefen M. Editorial Comment on: Oncologic Outcome and Patterns of
Recurrence after Salvage Radical Prostatectomy. Eur Urol. 2008 Jul 14.
Walz J, Suardi N, Shariat SF, Jeldres C, Perrotte P, Graefen M,
Widmer H, Arjane P, Valiquette L, Hutterer G, Saad F, Karakiewicz PI. Accuracy
of life tables in predicting overall survival in patients after radical
prostatectomy. BJU Int. 2008 Jul;102(1):33-8.
Schwarzenbach H, Chun FK, Müller I, Seidel C, Urban K, Erbersdobler
A, Huland H, Pantel K, Friedrich MG. Microsatellite analysis of allelic
imbalance in tumour and blood from patients with prostate cancer. BJU Int.
2008 Jul;102(2):253-8.
Jeldres C, Suardi N, Saad F, Montorsi F, Shariat SF, Perrotte P,
Bhojani N, Walz J, Hutterer GC, Graefen M, Valiquette L, Karakiewicz PI. High
provider volume is associated with lower rate of secondary therapies after
definitive radiotherapy for localized prostate cancer. Eur Urol. 2008 Jul;54(1):97-105.
Jeldres C, Suardi N, Walz J, Saad F, Hutterer GC, Bhojani N,
Shariat SF, Perrotte P, Graefen M, Montorsi F, Karakiewicz PI. Poor
overall survival in septa- and octogenarian patients after radical
prostatectomy and radiotherapy for prostate cancer: a population-based
study of 6183 men. Eur Urol. 2008 Jul;54(1):107-16.
Ahyai SA, Eichelberg C, Isbarn H, Zacharias M, Briganti A, Huland
H, Chun FK. Editorial Comment on: Prostate Cancer Detection Rate in
Patients with Repeated Extended 21-Sample Needle Biopsy. Eur Urol. 2008
Jun 23.
Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M,
Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, Briganti A, Shariat
SF, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI. Comparison of
stage migration patterns between Europe and the USA: an analysis of 11 350
men treated with radical prostatectomy for prostate cancer. BJU Int. 2008
Jun;101(12):1513-8.
Hellwinkel OJ, Rogmann JP, Asong LE, Luebke AM, Eichelberg C, Ahyai
S, Isbarn H, Graefen M, Huland H, Schlomm T. A comprehensive analysis of
transcript signatures of the phosphatidylinositol-3 kinase/protein kinase
B signal-transduction pathway in prostate cancer. BJU Int. 2008 Jun;101(11):1454-60.
Mathers MJ, Klotz T, Vahlensieck W, Zellner M, Lümmen G, Roth S,
Huland H, Sommer F. Is rehabilitation of erectile function following
pelvic surgery reasonable? Review of the literature: from sports to PDE5
inhibitors. Urologe A. 2008 Jun;47(6):685-92.
Schlomm T, Hellwinkel OJ, Buness A, Ruschhaupt M, Lübke AM, Chun
FK, Simon R, Budäus L, Erbersdobler A, Graefen M, Huland H, Poustka A,
Sültmann H. Molecular Cancer Phenotype in Normal Prostate Tissue. Eur
Urol. 2008 May 16.
Chun FK, Suardi N, Capitanio U, Jeldres C, Ahyai S, Graefen M,
Haese A, Steuber T, Erbersdobler A, Montorsi F, Huland H, Karakiewicz PI. Assessment
of Pathological Prostate Cancer Characteristics in Men with Favorable
Biopsy Features on Predominantly Sextant Biopsy. Eur Urol. 2008 May 15.
Isbarn H, Budäus L, Pichlmeier U, Conrad S, Huland H, Friedrich MG.
Comparison of the effectiveness between long-term instillation of
mitomycin C and short-term prophylaxis with MMC or bacille
Calmette-Guérin. Study of patients with non-muscle-invasive urothelial
cancer of the urinary bladder. Urologe A. 2008 May;47(5):608-15.
Walz J, Montorsi F, Jeldres C, Suardi N, Shariat SF, Perrotte P,
Arjane P, Graefen M, Pharand D, Karakiewicz PI. The effect of surgical
volume, age and comorbidities on 30-day mortality after radical
prostatectomy: a population-based analysis of 9208 consecutive cases. BJU
Int. 2008 Apr;101(7):826-32.
Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J,
Köllermann J, Briganti A, Zacharias M, Friedrich MG, Karakiewicz PI,
Montorsi F, Huland H, Chun FK. Contemporary prostate cancer prevalence
among T1c biopsy-referred men with a prostate-specific antigen level <
or = 4.0 ng per milliliter. Eur Urol. 2008 Apr;53(4):750-7.
Karakiewicz PI, Bhojani N, Neugut A, Shariat SF, Jeldres C, Graefen
M, Perrotte P, Peloquin F, Kattan MW. The effect of comorbidity and
socioeconomic status on sexual and urinary function and on general
health-related quality of life in men treated with radical prostatectomy
for localized prostate cancer. J Sex Med. 2008 Apr;5(4):919-27.
Suardi N, Porter CR, Reuther AM, Walz J, Kodama K, Gibbons RP,
Correa R, Montorsi F, Graefen M, Huland H, Klein EA, Karakiewicz PI. A
nomogram predicting long-term biochemical recurrence after radical
prostatectomy. Cancer. 2008 Mar 15;112(6):1254-63.
Salomon G, Hess T, Erbersdobler A, Eichelberg C, Greschner S,
Sobchuk AN, Korolik AK, Nemkovich NA, Schreiber J, Herms M, Graefen M,
Huland H. The Feasibility of Prostate Cancer Detection by Triple
Spectroscopy. Eur Urol. 2008 Mar 7.
Briganti A, Gallina A, Suardi N, Chun FK, Walz J, Heuer R, Salonia
A, Haese A, Perrotte P, Valiquette L, Graefen M, Rigatti P, Montorsi F,
Huland H, Karakiewicz PI. A nomogram is more accurate than a regression
tree in predicting lymph node invasion in prostate cancer. BJU Int. 2008
Mar;101(5):556-60.
Graefen M. Words of wisdom. Re: Identification of patients with
prostate cancer who benefit from immediate postoperative radiotherapy:
EORTC 22911. Eur Urol. 2008 Mar;53(3):664-5.
Chun FK. Editorial comment on: Prostate cancer characteristics in a
multiracial community. Eur Urol. 2008 Mar;53(3):538-9.
Karakiewicz PI, Chun FK, Gallina A, Suardi N, Briganti A,
Erbersdobler A, Schlomm T, Walz J, Currlin E, Michl U, Haese A, Arjane P,
Heinzer H, Graefen M, Huland H. Biopsies performed at tertiary care
centers are superior to referral biopsies in predicting pathologic Gleason
sum. J Endourol. 2008 Mar;22(3):533-8.
Graefen M, Ahyai S, Heuer R, Salomon G, Schlomm T, Isbarn H, Budäus
L, Heinzer H, Huland H. Active surveillance for prostate cancer. Urologe
A. 2008 Mar;47(3):261-9.
Schlomm T, Näkel E, Lübke A, Buness A, Chun FK, Steuber T, Graefen
M, Simon R, Sauter G, Poustka A, Huland H, Erbersdobler A, Sültmann H,
Hellwinkel OJ. Marked gene transcript level alterations occur early during
radical prostatectomy. Eur Urol. 2008 Feb;53(2):333-44.
Walz J, Suardi N, Hutterer GC, Perrotte P, Gallina A, Bénard F,
Valiquette L, McCormack M, Graefen M, Montorsi F, Karakiewicz PI. Lower
urinary tract symptoms affect one-third of men in a prostate cancer
screening population. J Endourol. 2008 Feb;22(2):369-76.
Walz J, Perrotte P, Suardi N, Hutterer G, Jeldres C, Bénard F,
Valiquette L, Graefen M, Montorsi F, Karakiewicz PI. Baseline prevalence
of erectile dysfunction in a prostate cancer screening population. J Sex
Med. 2008 Feb;5(2):428-35.
